Senesco Technologies Inc., of Bridgewater, N.J., said it closed enrollment in its ongoing open-label, multiple-dose, dose-escalation phase Ib/IIa trial of SNS01-T, a modulator of eukaryotic translation initiation factor 5A, or eIF5A, in patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B-cell lymphoma.